
Fibrous Sheath Dysplasia and Male Infertility Testing
Abnormal sperm tail structure impairs motility; fibrous sheath dysplasia is assessed by semen analysis, electron microscopy and testing of the Akap3 and Akap4 genes.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Abnormal sperm tail structure impairs motility; fibrous sheath dysplasia is assessed by semen analysis, electron microscopy and testing of the Akap3 and Akap4 genes.

Heart defects, pulmonary arterial hypertension, joint hypermobility and seizures can all follow Filamin A mutations, which pass in an X-linked dominant pattern.

Filamin B helps organize the actin cytoskeleton in bone; when FLNB is mutated the result can be Larsen syndrome, atelosteogenesis or boomerang dysplasia.

Discover the importance of genetic testing in diagnosing GARS-Associated Axonal Neuropathy, understanding disease progression, guiding family planning, and future therapies.

Blepharocheilodontic syndrome links familial diffuse gastric cancer with cleft lip through CDH1 variants, and testing supports diagnosis and risk assessment.

EGFR exon 19 deletions and the exon 21 L858R change mark tumors more likely to respond to gefitinib, while MET amplification and BRAF(V600E) shape resistance.

Resistance to gemcitabine in pancreatic ductal adenocarcinoma has been linked to SNPs, a seven-gene inflammatory signature and the PGM3 enzyme.

Patients differ in how they respond to gentamicin, and genetic testing may help predict that response, adjust dosing and limit kidney or hearing side effects.